Drug Profile
Sotagliflozin - Lexicon Pharmaceuticals
Alternative Names: INPEFA; LP-802034; LX-4211; SAR 439954; ZynquistaLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Lexicon Pharmaceuticals
- Developer Lexicon Pharmaceuticals; Sanofi
- Class Alcohols; Antihyperglycaemics; Chlorobenzenes; Glycosides; Heart failure therapies; Phenyl ethers; Pyrans; Small molecules; Sulfhydryl compounds
- Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Heart failure; Type 2 diabetes mellitus
- Registered Type 1 diabetes mellitus
Most Recent Events
- 28 Mar 2024 9413129: No updates, data from a post-hoc analysis of the P-III SCORED trial, hence not added
- 11 Mar 2024 Lexicon Pharmaceuticals plans to resubmit the NDA for Type 1 diabetes mellitus (Adjunctive treatment) in mid-2024
- 08 Jan 2024 Lexicon Pharmaceuticals plans to file sNDA for (line sotagliflozin for treatment of patients with Hypertrophic cardiomyopathy in USA (9407528)